Ozurdex launched in China for RVO

Ozurdex launched in China for RVO

Colin Kerr

Published: Tuesday, May 1, 2018

Allergan has announced the launch of Ozurdex (dexamethasone intravitreal implant 0.7mg) in China for the treatment of adult patients with macular oedema secondary to retinal vein occlusion (RVO). Ozurdex is the first approved intravitreal injection for RVO in China and is licensed for the treatment of macular oedema following BRVO and CRVO. “Providing millions of RVO patients access to Ozurdex is a significant step towards preventing blindness and meeting a critical unmet need in China,” said Marc Princen, Allergan International President. http://www.allergan.com/

Latest Articles

Simulators Benefit Surgeons and Patients

Helping young surgeons build confidence and expertise.

How Many Surgeries Equal Surgical Proficiency?

Internet, labs, simulators, and assisting surgery all contribute.

Improving Clinical Management for nAMD and DME

Global survey data identify barriers and opportunities.

Are Postoperative Topical Antibiotic Drops Still Needed?

Cataract surgeons debate the benefits of intracameral cefuroxime prophylaxis.

Emerging Technology for Detecting Subclinical Keratoconus

Brillouin microscopy shows promise in clinical studies.

Knowing Iris Repair: Modified Trifold Technique

Part eight of our series covers the modified trifold technique for large iris defects.

It’s All About Biomechanics!

Increasing the pool of patients eligible for refractive surgery.

Uncovering More Safe and Quick Options

Different strategies, such as PresbyLASIK, can offer presbyopes good outcomes.

Topography-Guided PRK for Keratoconus

Improving visual acuity in patients with keratoconus.

Defining AMD Treatment Protocol

Treatments trending to fewer injections for better results.